[Treatment of chronic hepatitis C: shorter treatment duration for genotype 2 or 3 infection]

Korean J Hepatol. 2007 Sep;13(3):301-3. doi: 10.3350/kjhep.2007.13.3.301.

[Article in Korean]

Author

Sook Hyang Jeong¹

Affiliation

¹ Department of Internal Medicine, Seoul National University Bundang Hospital, Gyeonggi, Korea.

PMID: 17898546
DOI: 10.3350/kjhep.2007.13.3.301

No abstract available

Publication types

Comment

MeSH terms

Antiviral Agents / administration & dosage*
Antiviral Agents / therapeutic use
Drug Therapy, Combination
Genotype
Hepacivirus / genetics
Hepatitis C, Chronic / drug therapy*
Humans
Interferon alpha-2
Interferon-alpha / administration & dosage
Interferon-alpha / therapeutic use
Polyethylene Glycols / administration & dosage
Polyethylene Glycols / therapeutic use
Recombinant Proteins
Ribavirin / administration & dosage
Ribavirin / therapeutic use
Time Factors
Treatment Outcome

Substances

Antiviral Agents
Interferon alpha-2
Interferon-alpha
Recombinant Proteins
Polyethylene Glycols
Ribavirin
peginterferon alfa-2b
peginterferon alfa-2a